Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 49.42 (-0.98), ANIP: 60.38 (-0.68), INGN: 52.89 (-0.11), GLYC: 8.78 (-0.06)
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:30AM CDT
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
CSGP: 203.02 (-2.38), CW: 87.78 (-1.25), INGN: 52.89 (-0.11), HLS: 41.68 (-0.37), PKI: 55.70 (-0.99)
Top Stocks with Big Potential Catch-Up Moves
Kevin Matras - ZACKS - Tue Jul 26, 2:31PM CDT
Top Stocks with Big Potential Catch-Up Moves
CSGP: 203.02 (-2.38), CW: 87.78 (-1.25), INGN: 52.89 (-0.11), HLS: 41.68 (-0.37), PKI: 55.70 (-0.99)
Inogen Announces Participation in 36th Annual William Blair Growth Stock Conference
BusinessWire - Wed Jun 01, 3:05PM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Company will be participating in the 36th Annual William Blair Growth Stock Conference.
INGN: 52.89 (-0.11)
Inogen (INGN) Introduces Next-Gen Inogen One G4 POC
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:15AM CDT
Inogen Inc (INGN) recently launched a next-generation portable oxygen concentrator (POC) -- Inogen One G4.
MASI: 52.58 (-0.35), INGN: 52.89 (-0.11), EXAC: 27.00 (-0.20), CRY: 14.10 (-0.22)
Inogen Releases Innovative Inogen One G4(TM) Oxygen Concentrator
BusinessWire - Tue May 31, 7:00AM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the release to market of its innovative Inogen One G4 portable oxygen concentrator. The ultra-portable device is the smallest and lightest oxygen concentrator that the Company has ever produced, and the Company expects the product to be embraced by long-term oxygen therapy users worldwide.
INGN: 52.89 (-0.11)
Inogen Announces Investor/Analyst Day and Webcast
BusinessWire - Tue May 24, 6:30AM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it will host an institutional investor and analyst meeting on Tuesday, June 7, 2016 in Los Angeles, CA, from 1:00 p.m. to 3:30 p.m. PT. The meeting will include presentations from company executives and Vernon Pertelle, President and CEO of StratiHealth and President and Executive Director of Pulmonary Horizons Health, an industry expert in homecare respiratory therapy.
INGN: 52.89 (-0.11)
Inogen misses 1Q profit forecasts
Automated Insights - Mon May 09, 3:25PM CDT
GOLETA, Calif. (AP) _ Inogen Inc. (INGN) on Monday reported first-quarter net income of $2.4 million.
INGN: 52.89 (-0.11)
Inogen Announces First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
--- Q1 2016 Net Income up 50.4% Over the Same Period in 2015 -
INGN: 52.89 (-0.11)
Med Instruments Stocks' Q1 Earnings: PEN, INGN, OPKO, NVRO
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:33AM CDT
Watch out for Medical Instrument stocks PEN, INGN, OPKO and NVRO reporting first-quarter results on May 9.
OPK: 9.88 (-0.19), INGN: 52.89 (-0.11), PEN: 68.41 (-0.12), NVRO: 81.03 (-1.31)
Inogen (INGN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:51PM CDT
Inogen Inc. (INGN) is scheduled to report first-quarter 2016 results on May 9
XON: 26.13 (-1.25), INGN: 52.89 (-0.11), QSII: 12.02 (-0.18), COO: 182.33 (-0.28)
DexCom (DXCM) Q1 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:46AM CDT
Shares of DexCom Inc. (DXCM) fell 3.6% to close at $65.96 on Apr 28, following a disappointing first-quarter 2016 earnings release.
ANTM: 127.38 (-0.23), DXCM: 92.00 (-0.65), INGN: 52.89 (-0.11), EXAC: 27.00 (-0.20)
Inogen Announces Updated Time for First Quarter 2016 Results Earnings Conference Call - Monday, May 9, 2016, 2:30 PM PT / 5:30 PM ET
BusinessWire - Thu Apr 28, 3:01PM CDT
Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the previously announced conference call with management to discuss first quarter 2016 results will now be held at 2:30pm PT/5:30pm ET on Monday, May 9, 2016. Results for the quarter will be released after the market closes on the same day.
INGN: 52.89 (-0.11)
Varian (VAR) Beats Q2 Earnings by a Penny, Lags Revenues
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:19AM CDT
Varian Medical Systems Inc. (VAR) reported earnings of $1.09 per share in the second quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a penny.
RTIX: 3.11 (+0.01), VAR: 94.38 (-0.46), INGN: 52.89 (-0.11), EXAC: 27.00 (-0.20)
Accuray (ARAY) Posts Earnings in Q3, Down on View Cut
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:55AM CDT
Shares of Accuray Inc. (ARAY) fell 3.3% in after-hours trading following the company's third-quarter fiscal 2016 results and trimmed fiscal 2016 guidance.
INGN: 52.89 (-0.11), EXAC: 27.00 (-0.20), ARAY: 5.43 (-0.02), HOLX: 39.15 (+0.17)
Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 8.28 (-0.34), GMED: 23.63 (+0.14), INGN: 52.89 (-0.11), EXAC: 27.00 (-0.20)
Intuitive Surgical (ISRG): Stock Set to Top Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 2:10PM CDT
Intuitive Surgical Inc. (ISRG) set to report first-quarter 2016 results on Apr 19.
ISRG: 686.55 (-7.32), ZBH: 129.86 (-1.20), ALGN: 89.75 (+0.06), INGN: 52.89 (-0.11)
Mazor Robotics: Strong Sell as Orders Register a Decline
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 12:00PM CDT
On Apr 14, Zacks Investment Research downgraded Mazor Robotics Ltd (MZOR) to a Zacks Rank #5 (Strong Sell).
VAR: 94.38 (-0.46), GMED: 23.63 (+0.14), INGN: 52.89 (-0.11), MZOR: 21.62 (-0.94)
Q1 Earnings Lack Sheen: 5 MedTech Stocks to Bet On
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 3:55PM CDT
Medical is one of the few sectors in the S&P 500 that is expected to report growth in the first quarter.
ZBH: 129.86 (-1.20), ALGN: 89.75 (+0.06), GKOS: 33.70 (-0.23), QDEL: 22.75 (-0.38), INGN: 52.89 (-0.11)